Comparing Epclusa vs Mavyret
| Epclusa (sofosbuvir / velpatasvir) | Mavyret (glecaprevir / pibrentasvir) |
|
|---|
| Epclusa (sofosbuvir / velpatasvir) | Mavyret (glecaprevir / pibrentasvir) |
|
|||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Prescription only
Epclusa is used to treat adults and children 3 years and older with chronic HCV genotype 1, 2, 3, 4, 5, or 6 infection without cirrhosis or with compensated cirrhosis. For decompensated cirrhosis it... View more |
Prescription only
Mavyret is an antiviral combination agent that is approved to treat all six genotypes (1-6) of acute or chronic hepatitis C virus (HCV) infection in adults and children aged 12 years of age and... View more |
Related suggestions Hepatitis C
Popular comparisons
|
|||||||||||||||
| More about Epclusa (sofosbuvir / velpatasvir) | More about Mavyret (glecaprevir / pibrentasvir) | ||||||||||||||||
| Ratings & Reviews | |||||||||||||||||
|
Epclusa has an average rating of 7.6 out of 10 from a total of 407 ratings on Drugs.com. 61% of reviewers reported a positive effect, while 12% reported a negative effect. |
Mavyret has an average rating of 8.3 out of 10 from a total of 428 ratings on Drugs.com. 76% of reviewers reported a positive effect, while 7% reported a negative effect. |
||||||||||||||||
| Side Effects Experienced by Users Side effects are reported in Drugs.com user reviews and not clinically verified. | |||||||||||||||||
View all Epclusa side effects |
View all Mavyret side effects |
||||||||||||||||
| Drug Class | |||||||||||||||||
| Generic Availability | |||||||||||||||||
| Pricing and Coupons * Prices are without insurance | |||||||||||||||||
View all Epclusa prices |
View all Mavyret prices |
||||||||||||||||
| Dosage Forms | |||||||||||||||||
|
|
||||||||||||||||
| Brand Names | |||||||||||||||||
|
N/A |
N/A |
||||||||||||||||
| Half Life Drug half-life is the time required for plasma concentration to reduce to half its original value. | |||||||||||||||||
|
27 hours |
13 hours |
||||||||||||||||
| CSA Schedule 1 View glossary of CSA terms | |||||||||||||||||
|
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||||||||||
| Pregnancy Category | |||||||||||||||||
|
Summary unavailable. See the full pregnancy warnings document. |
Summary unavailable. See the full pregnancy warnings document. |
||||||||||||||||
| Drug Interactions | |||||||||||||||||
|
A total of 201 drugs are known to interact with Epclusa:
|
A total of 218 drugs are known to interact with Mavyret:
|
||||||||||||||||
| Alcohol/Food/Lifestyle Interactions | |||||||||||||||||
|
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
|
||||||||||||||||
| Disease Interactions | |||||||||||||||||
| First Approval Date | |||||||||||||||||
|
June 28, 2016 |
August 03, 2017 |
||||||||||||||||
| WADA Class View classifications | |||||||||||||||||
|
N/A |
N/A |
||||||||||||||||
| More Information | |||||||||||||||||
| Patient Resources | |||||||||||||||||
| Professional Resources | |||||||||||||||||
| Related Treatment Guide | |||||||||||||||||
1 The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
See also:
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.